Pharmacy Compounding is the creation of a personalized drug to meet the unique needs of a patient. It is performed by a licensed pharmacist, a licensed physician or a person under the supervision of a licensed pharmacist. In Hospitals and Compounding Labs worldwide, an enormous number of oncology treatments are prepared every day. There are several key persons involved in the antiblastics preparation process: oncologists, pharmacists, nurses and health technicians. It’s important to have full collaboration between these parties in order to avoid mistakes and allow the patient to receive a tailor made drug that is precise in dosage and fully sterile, in a reasonable timeframe.
Despite the importance of pharmacy compounding, there are many risks associated to this activity. Compounded preparations are not FDA-approved; this means that the safety standards are often lower compared to the requirements of the pharmaceutical industry. In the majority of cases, antiblastic drugs are nowadays compounded manually under a laminar flow hood. There are several limits to this approach:
Existing robotic pharmacy compounding systems only replicate manual operations without any real optimization of the whole compounding process: therapies are prepared one after the other in the order of prescription. The main consequence of this is the fact that pharmacies still have a very low control of drug waste and related costs. More in general, existing robotic compounding systems have the following limits:
Pharmoduct, Automatic Compounding System is a patented device for the sterile preparation of personalised oncology drugs, including chemotherapy and biologicals. Pharmoduct is able to reconstitute, transfer and dilute oncology drugs in order to prepare final doses (patient specific) and multi-dose bags (pharmacy bulk package). The system can manage more than 300 different drugs. The introduction of Pharmoduct in the Compounding Lab will improve the whole oncology drugs preparation workflow.
Multi-dose bags preparation
Final containers preparation
HL7 integration with e-prescribing software
Pharmoduct is conceived to be easily integrated with existing e-prescribing software, in order to maximize the efficiency of the whole chemotherapy workflow. (About HL7).
Once therapies are prescribed by oncologist and validated by pharmacist, become visible directly in the screen of the
system – ready to be compounded.
Unlike other robotic compounding systems – that prepare doses one after the other, following the order of prescription – Pharmoduct groups them by drug (API, Active Pharmaceutical Ingredient) and operate through a batch approach.
This method allows to acquire, quantify and use the whole quantity of drug present within the vials.
All Luer Lock final containers compatibility
Pharmoduct is able to compound doses in all existing final containers with Luer Lock connection. Thanks to dedicated adaptors and support, even containers of new generation can be easily used.
The system can manage up to 15 final preparations in one batch, even of different typologies in the same session.